I keep a close eye on reports about B-cells and T-cells because they’re the targets of Lemtrada, which is my current disease-modifying therapy. (The DMT Ocrevus targets B-cells alone). So, this research, which offers confirmation that B- and T-cells interact to attack myelin, should be encouraging news for everyone with MS; and particularly encouraging for those of us who hope that Lemtrada or Ocrevus will stop their MS dead in its tracks.
B-cells in the immune system play an important role in the unfolding of inflammation and brain lesions in multiple sclerosis, largely by how they influence the actions of another immune system cell, called T-cells, a new study reports.
Its findings help explain why therapies like Ocrevus and off-label use of rituximab, both of which act on B-cells, are effective in controlling MS.
The study, “Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis,” was published in the journal CNS Drugs.
Many of us with MS have sexual problems but few of us talk about them, at least not outside of some private MS social media groups. This study confirms that there’s a sexual silence between MS patients and their physicians. The study may increase the knowledge of the medical professionals who treat us but it certainly doesn’t tell us anything we patients don’t already know.
The study, “Factors associated with sexual dysfunction in individuals with multiple sclerosis,” was published in the International Journal of MS Care.
Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.